Pharmacy Department, OSF Healthcare Saint Francis Medical Center/Children's Hospital of Illinois, 530 NE Glen Oak AVE, Peoria, IL, 61637, USA.
Pediatrics Department, University of Illinois College of Medicine Peoria, OSF Healthcare Children's Hospital of Illinois, Peoria, IL, USA.
Paediatr Drugs. 2021 Nov;23(6):575-582. doi: 10.1007/s40272-021-00472-0. Epub 2021 Oct 11.
Our objective was to describe the efficacy and safety of furosemide and chlorothiazide combination continuous infusion (FCCCI) in children in a pediatric intensive care unit (ICU), including postoperative cardiac patients.
This was a retrospective cohort study in a pediatric ICU within a tertiary care teaching hospital. Children aged < 18 years admitted from 1 January 2010 to 31 December 2019 were included if they received a furosemide infusion for at least 6 h and then transitioned to FCCCI. Each patient acted as their own control.
A total of 203 patients (107 [53%] postoperative cardiac) met the study inclusion criteria. The study population was 55% male and 74% Caucasian, with a median age of 4.9 months. Of the total patients, 143 (70.4%) required mechanical ventilation and 39 (19.2%) required dialysis. The median duration of furosemide and FCCCI was 24.6 h (interquartile range [IQR] 12.4-54) and 41 h (IQR 15-162), respectively. Urine output increased by 52% with FCCCI (mean increase of 2.2 mL/kg/h [95% confidence interval {CI} 1.8-2.5]; p < 0.01). The change to FCCCI led to a net negative daily fluid balance (mean difference - 301.9 mL/day [95% CI - 390.9 to - 212.9]; p < 0.01). FCCCI resulted in a greater requirement for potassium bolus supplementation (mean increase of 12.8 boluses [95% CI 8.5-17.2]; p < 0.01) and a small but statistically significant increase in serum creatinine (mean difference 0.1 mg/dL [95% CI 0.06-0.14]; p < 0.01) with a resultant decrease in estimated glomerular filtration rate (mean difference - 13.5 [95% CI 9.7-17.4]; p < 0.01). Of the furosemide-refractory patients, 78.9% were responsive to FCCCI. Younger patients and patients who underwent cardiothoracic surgery were more likely to be responsive. Nonresponders to FCCCI had slightly higher mortality (21 vs. 6.6%, p = 0.05).
FCCCI resulted in a significant improvement in diuresis with achievement of negative fluid balance in pediatric ICU patients. FCCCI is a reasonable approach to aggressive diuresis in the pediatric patient, particularly in patients with limited access. Serum potassium should be routinely monitored during such therapy.
描述呋塞米和氯噻嗪联合持续输注(FCCCI)在儿科重症监护病房(PICU)中包括心脏术后患儿的疗效和安全性。
这是在一家三级教学医院的儿科 PICU 中进行的回顾性队列研究。纳入 2010 年 1 月 1 日至 2019 年 12 月 31 日至少接受 6 小时呋塞米输注,然后转为 FCCCI 的<18 岁患儿。每位患者自身为对照。
共有 203 名(107 名[53%]为心脏术后)患儿符合研究纳入标准。研究人群中 55%为男性,74%为白种人,中位年龄为 4.9 个月。在所有患儿中,143 名(70.4%)需要机械通气,39 名(19.2%)需要透析。呋塞米和 FCCCI 的中位持续时间分别为 24.6 小时(IQR 12.4-54)和 41 小时(IQR 15-162)。FCCCI 使尿量增加 52%(平均增加 2.2 mL/kg/h[95%置信区间{CI}1.8-2.5];p<0.01)。转为 FCCCI 导致每日净液体负平衡(平均差值-301.9 mL/天[95%CI-390.9 至-212.9];p<0.01)。FCCCI 导致需要更多的钾推注补充(平均增加 12.8 个推注[95%CI 8.5-17.2];p<0.01),血清肌酐略有但具有统计学意义的升高(平均差值 0.1 mg/dL[95%CI 0.06-0.14];p<0.01),肾小球滤过率估计值降低(平均差值-13.5[95%CI 9.7-17.4];p<0.01)。在呋塞米耐药的患儿中,78.9%对 FCCCI 有反应。年龄较小的患儿和接受心胸外科手术的患儿更可能有反应。FCCCI 无反应的患儿死亡率略高(21%比 6.6%,p=0.05)。
FCCCI 可显著改善儿科 ICU 患儿的利尿作用,实现液体负平衡。FCCCI 是儿科患者积极利尿的合理方法,特别是在通路有限的患者中。在这种治疗期间应常规监测血清钾。